Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Pharmaceutical Innovation

• Publication date

  2017-02-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12247-017-9277-xPMID 28966696PMCID PMC5614454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The January effect: medication reinitiation among Medicare Part D beneficiaries.

  2014cited by this paper
• How does drug treatment for diabetes compare between Medicare Advantage prescription drug plans (MAPDs) and stand-alone prescription drug plans (PDPs)?

  2013cited by this paper
• What is the value of ‘me-too’ drugs?

  2013cited by this paper
• Me-too drugs and me-too people.

  2013cited by this paper
• Does managed care affect the diffusion of psychotropic medications?

  2012cited by this paper
• Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer.

  2012cited by this paper
• Adoption of new drugs by physicians: a survival analysis

  2012cited by this paper
• Comparison of Statin Adherence Among Beneficiaries in MA-PD Plans Versus PDPs

  2012cited by this paper
• Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model

  2012cited by this paper
• Comments on "A New Product Growth for Model Consumer Durables The Bass Model"

  2004cited by this paper
• Diffusion of New Products: Empirical Generalizations and Managerial Uses

  1995cited by this paper
• Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee.

  1995cited by this paper

• THE PHARMACEUTICAL MARKET: a transdisciplinary description of concepts and their implications.

  2026cites this paper
• Factors influencing drug diffusion: a practical guide to the use of medicare part D claims

  2026cites this paper
• Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

  2023cites this paper
• Impact on In‐ and Out‐of‐Hospital Drug Prescriptions of Including a More Expensive Me‐Too Antidepressant in a Hospital Drug Formulary: a Controlled Longitudinal Study

  2021cites this paper
• The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs.

  2019cites this paper
• The Price of Substitute Technologies.

  2019cites this paper
• Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications

  2019cites this paper
• Translating Patient Value to Commercial Value in the Development of Digitally Measured Nocturnal Scratch

  year unknowncites this paper